WAVE Life Sciences (NASDAQ:WVE) Stock Price Up 5.9% – Still a Buy?

WAVE Life Sciences Ltd. (NASDAQ:WVE)’s share price rose 5.9% on Friday . The company traded as high as $6.62 and last traded at $6.5650. Approximately 5,741,936 shares traded hands during trading, an increase of 37% from the average daily volume of 4,196,267 shares. The stock had previously closed at $6.20.

WAVE Life Sciences News Summary

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company press release: management highlighted six‑month, placebo‑adjusted improvements in body composition (240 mg single dose produced ~14% visceral fat reduction, ~5% total fat reduction, +2% lean mass, ~3.3% waist circumference reduction) and continued safety/tolerability — data that supports the therapy’s mechanism and future development plans. Wave press release
• Positive Sentiment: Management commentary / transcripts emphasize the visceral‑fat and body‑composition signal and durability at six months, which supporters point to as a differentiated outcome versus pure body‑weight endpoints. Seeking Alpha transcript
• Positive Sentiment: Analyst positioning remains mixed but includes continued conviction from some firms: Bank of America kept a Buy rating (PT cut), Wells Fargo kept Overweight (PT cut), Truist upgraded to Strong‑Buy and Mizuho issued bullish commentary — these voices can limit downside and attract buyers after the sell‑off. Benzinga (analyst notes)
• Neutral Sentiment: Independent outlets and investor notes characterize the data as “clinically interesting” on body composition but still early‑stage and not yet persuasive on meaningful weight loss — meaning future development and larger trials will determine value. ProactiveInvestors report
• Negative Sentiment: Market reaction: shares plunged >50% after investors focused on the modest ~0.9% body‑weight reduction at six months and the higher‑dose readout that “failed to show a clear improvement” by some measures — the gap between body‑composition signals and headline weight loss disappointed traders. Reuters
• Negative Sentiment: Investor/legal risk: a law firm is publicizing an investigation into potential claims by shareholders, adding litigation overhang and downward pressure on sentiment. GlobeNewswire (Johnson Fistel)
• Negative Sentiment: Analyst downgrades and target cuts followed the update; multiple outlets report steep target cuts and downgrades that reflect lower near‑term expectations and have likely amplified selling pressure. Seeking Alpha downgrade

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on WVE shares. UBS Group set a $32.00 target price on WAVE Life Sciences in a report on Tuesday, December 16th. Raymond James Financial reaffirmed an “outperform” rating and set a $21.00 price target on shares of WAVE Life Sciences in a report on Monday, December 8th. Citigroup lifted their price objective on shares of WAVE Life Sciences from $16.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of WAVE Life Sciences in a research note on Monday, March 2nd. Finally, Royal Bank Of Canada upgraded shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $9.00 to $27.00 in a research report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $31.38.

WAVE Life Sciences Stock Performance

The company has a market cap of $1.20 billion, a price-to-earnings ratio of -5.21 and a beta of -1.77. The company has a 50-day simple moving average of $12.93 and a 200-day simple moving average of $11.22.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The business had revenue of $17.25 million during the quarter, compared to analyst estimates of $15.68 million. As a group, equities research analysts forecast that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

Insiders Place Their Bets

In other news, insider Chandra Vargeese sold 3,228 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $43,416.60. Following the transaction, the insider directly owned 408,246 shares of the company’s stock, valued at $5,490,908.70. This represents a 0.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Chris Francis sold 33,194 shares of the stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the completion of the transaction, the insider owned 61,867 shares of the company’s stock, valued at $931,098.35. This represents a 34.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 61,748 shares of company stock worth $907,809 in the last ninety days. 23.98% of the stock is owned by insiders.

Institutional Trading of WAVE Life Sciences

A number of institutional investors have recently added to or reduced their stakes in the stock. CWM LLC increased its holdings in WAVE Life Sciences by 6,729.0% in the fourth quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after buying an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of WAVE Life Sciences by 645.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after acquiring an additional 1,942 shares during the period. Bessemer Group Inc. boosted its stake in shares of WAVE Life Sciences by 1,156.3% during the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock worth $72,000 after acquiring an additional 9,135 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of WAVE Life Sciences by 1,441.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after acquiring an additional 9,284 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of WAVE Life Sciences by 18.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after acquiring an additional 1,802 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.